Schmid P, Salgado R, Park YH, Munoz-Couselo E, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 2020 Feb 14. pii: S0923-7534(20)36032.
PMID: 32278621